Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology

Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if admini...

Descripción completa

Detalles Bibliográficos
Autores principales: Cognasse, Fabrice, Hamzeh-Cognasse, Hind, Duchez, Anne-Claire, Shurko, Natalia, Eyraud, Marie-Ange, Arthaud, Charles-Antoine, Prier, Amélie, Heestermans, Marco, Hequet, Olivier, Bonneaudeau, Brigitte, Rochette-Eribon, Sandrine, Teyssier, Françoise, Barlet-Excoffier, Valérie, Chavarin, Patricia, Legrand, Dominique, Richard, Pascale, Morel, Pascal, Mooney, Nuala, Tiberghien, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585295/
https://www.ncbi.nlm.nih.gov/pubmed/36275757
http://dx.doi.org/10.3389/fimmu.2022.1034379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585295/
https://www.ncbi.nlm.nih.gov/pubmed/36275757
http://dx.doi.org/10.3389/fimmu.2022.1034379

Ejemplares similares